Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19), hepatitis B Virus (HBV) and human metapneumovirus (hMPV).

Learn More »

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

September 17, 2023
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
September 7, 2023
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

Upcoming Events